Details for New Drug Application (NDA): 215290
✉ Email this page to a colleague
NDA 215290 describes ERYTHROMYCIN LACTOBIONATE, which is a drug marketed by Abraxis Pharm, Baxter Hlthcare, Exela Pharma, Nexus, and Teva Parenteral, and is included in five NDAs. It is available from two suppliers. Additional details are available on the ERYTHROMYCIN LACTOBIONATE profile page.
The generic ingredient in ERYTHROMYCIN LACTOBIONATE is erythromycin lactobionate. There are one hundred and three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the erythromycin lactobionate profile page.
The generic ingredient in ERYTHROMYCIN LACTOBIONATE is erythromycin lactobionate. There are one hundred and three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the erythromycin lactobionate profile page.
Summary for 215290
| Tradename: | ERYTHROMYCIN LACTOBIONATE |
| Applicant: | Nexus |
| Ingredient: | erythromycin lactobionate |
| Patents: | 0 |
Pharmacology for NDA: 215290
| Physiological Effect | Decreased Sebaceous Gland Activity |
Suppliers and Packaging for NDA: 215290
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 215290 | ANDA | Nexus Pharmaceuticals LLC | 14789-116 | 14789-116-05 | 5 VIAL, GLASS in 1 BOX (14789-116-05) / 10 mL in 1 VIAL, GLASS (14789-116-07) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | Feb 14, 2022 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
